RadNet - RDNT Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RDNT shares.
View RDNT analyst ratings or view top-rated stocks.

1 analysts have issued 12 month price targets for RadNet's shares. Their RDNT share price forecasts range from $30.00 to $30.00. On average, they anticipate the company's share price to reach $30.00 in the next year. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for RDNT or view top-rated stocks among Wall Street analysts.

RadNet's stock was trading at $18.83 at the beginning of 2023. Since then, RDNT shares have increased by 24.0% and is now trading at $23.35.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our RDNT earnings forecast.

RadNet, Inc. (NASDAQ:RDNT) announced its earnings results on Tuesday, February, 28th. The medical research company reported $0.11 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by $0.08. The medical research company had revenue of $383.90 million for the quarter, compared to analyst estimates of $347.27 million. RadNet had a trailing twelve-month return on equity of 2.64% and a net margin of 0.74%. RadNet's revenue for the quarter was up 15.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.13 earnings per share.

ETFs with the largest weight of RadNet (NASDAQ:RDNT) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Services ETF (XHS), iShares Micro-Cap ETF (IWC), SPDR S&P 600 Small CapValue ETF (SLYV), iShares U.S. Healthcare Providers ETF (IHF), iShares S&P Small-Cap 600 Value ETF (IJS) and Vanguard S&P Small-Cap 600 Value ETF (VIOV).Invesco S&P SmallCap 600 Equal Weight ETF (EWSC).

RadNet updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.54 billion-$1.59 billion, compared to the consensus revenue estimate of $1.46 billion.

174 employees have rated RadNet Chief Executive Officer Howard G. Berger on Glassdoor.com. Howard G. Berger has an approval rating of 45% among the company's employees. This puts Howard G. Berger in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), OPKO Health (OPK), Boeing (BA), Rigel Pharmaceuticals (RIGL), UnitedHealth Group (UNH), Pfizer (PFE) and AT&T (T).

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

RadNet's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Beck Mack & Oliver LLC (5.60%), Edmond DE Rothschild Holding S.A. (4.46%), Dimensional Fund Advisors LP (2.68%), Global Alpha Capital Management Ltd. (2.65%), Geode Capital Management LLC (1.63%) and Silvercrest Asset Management Group LLC (1.19%). Insiders that own company stock include Christine Nayoma Gordon, David L Swartz, John V Crues, Lawrence L Levitt, Lawrence L Levitt, Michael N Murdock, Norman R Hames and Ruth Louisa Villigerwilson.
View institutional ownership trends.

Shares of RDNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RDNT stock can currently be purchased for approximately $23.35.

RadNet (NASDAQ:RDNT) has a market capitalization of $1.35 billion and generates $1.43 billion in revenue each year. The medical research company earns $10.65 million in net income (profit) each year or $0.17 on an earnings per share basis.

The company employs 9,067 workers across the globe.

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The official website for the company is www.radnet.com. The medical research company can be reached via phone at (310) 445-2800, via email at investorrelations@radnet.com, or via fax at 310-445-2980.